Cargando…

Impact of Plasma Xanthine Oxidoreductase Activity on the Mechanisms of Distal Symmetric Polyneuropathy Development in Patients with Type 2 Diabetes

To unravel associations between plasma xanthine oxidoreductase (XOR) and diabetic vascular complications, especially distal symmetric polyneuropathy (DSP), we investigated plasma XOR activities using a novel assay. Patients with type 2 diabetes mellitus (T2DM) with available nerve conduction study (...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujishiro, Midori, Ishihara, Hisamitsu, Ogawa, Katsuhiko, Murase, Takayo, Nakamura, Takashi, Watanabe, Kentaro, Sakoda, Hideyuki, Ono, Hiraku, Yamamotoya, Takeshi, Nakatsu, Yusuke, Asano, Tomoichiro, Kushiyama, Akifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391363/
https://www.ncbi.nlm.nih.gov/pubmed/34440256
http://dx.doi.org/10.3390/biomedicines9081052
_version_ 1783743257347358720
author Fujishiro, Midori
Ishihara, Hisamitsu
Ogawa, Katsuhiko
Murase, Takayo
Nakamura, Takashi
Watanabe, Kentaro
Sakoda, Hideyuki
Ono, Hiraku
Yamamotoya, Takeshi
Nakatsu, Yusuke
Asano, Tomoichiro
Kushiyama, Akifumi
author_facet Fujishiro, Midori
Ishihara, Hisamitsu
Ogawa, Katsuhiko
Murase, Takayo
Nakamura, Takashi
Watanabe, Kentaro
Sakoda, Hideyuki
Ono, Hiraku
Yamamotoya, Takeshi
Nakatsu, Yusuke
Asano, Tomoichiro
Kushiyama, Akifumi
author_sort Fujishiro, Midori
collection PubMed
description To unravel associations between plasma xanthine oxidoreductase (XOR) and diabetic vascular complications, especially distal symmetric polyneuropathy (DSP), we investigated plasma XOR activities using a novel assay. Patients with type 2 diabetes mellitus (T2DM) with available nerve conduction study (NCS) data were analyzed. None were currently taking XOR inhibitors. XOR activity of fasting blood samples was assayed using a stable isotope-labeled substrate and LC-TQMS. JMP Clinical version 5.0. was used for analysis. We analyzed 54 patients. Mean age was 64.7 years, mean body mass index was 26.0 kg/m(2), and mean glycated hemoglobin was 9.4%. The logarithmically transformed plasma XOR activity (ln-XOR) correlated positively with hypoxanthine, xanthine, visceral fatty area, and liver dysfunction but negatively with HDL cholesterol. ln-XOR correlated negatively with diabetes duration and maximum intima-media thickness. Stepwise multiple regression analysis revealed ln-XOR to be among selected explanatory factors for various NCS parameters. Receiver operating characteristic curves showed the discriminatory power of ln-XOR. Principal component analysis revealed a negative relationship of ln-XOR with F-waves as well as positive relationships of ln-XOR with hepatic steatosis and obesity-related disorders. Taken together, our results show plasma XOR activity to be among potential disease status predictors in T2DM patients. Plasma XOR activity measurements might reliably detect pre-symptomatic DSP.
format Online
Article
Text
id pubmed-8391363
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83913632021-08-28 Impact of Plasma Xanthine Oxidoreductase Activity on the Mechanisms of Distal Symmetric Polyneuropathy Development in Patients with Type 2 Diabetes Fujishiro, Midori Ishihara, Hisamitsu Ogawa, Katsuhiko Murase, Takayo Nakamura, Takashi Watanabe, Kentaro Sakoda, Hideyuki Ono, Hiraku Yamamotoya, Takeshi Nakatsu, Yusuke Asano, Tomoichiro Kushiyama, Akifumi Biomedicines Article To unravel associations between plasma xanthine oxidoreductase (XOR) and diabetic vascular complications, especially distal symmetric polyneuropathy (DSP), we investigated plasma XOR activities using a novel assay. Patients with type 2 diabetes mellitus (T2DM) with available nerve conduction study (NCS) data were analyzed. None were currently taking XOR inhibitors. XOR activity of fasting blood samples was assayed using a stable isotope-labeled substrate and LC-TQMS. JMP Clinical version 5.0. was used for analysis. We analyzed 54 patients. Mean age was 64.7 years, mean body mass index was 26.0 kg/m(2), and mean glycated hemoglobin was 9.4%. The logarithmically transformed plasma XOR activity (ln-XOR) correlated positively with hypoxanthine, xanthine, visceral fatty area, and liver dysfunction but negatively with HDL cholesterol. ln-XOR correlated negatively with diabetes duration and maximum intima-media thickness. Stepwise multiple regression analysis revealed ln-XOR to be among selected explanatory factors for various NCS parameters. Receiver operating characteristic curves showed the discriminatory power of ln-XOR. Principal component analysis revealed a negative relationship of ln-XOR with F-waves as well as positive relationships of ln-XOR with hepatic steatosis and obesity-related disorders. Taken together, our results show plasma XOR activity to be among potential disease status predictors in T2DM patients. Plasma XOR activity measurements might reliably detect pre-symptomatic DSP. MDPI 2021-08-19 /pmc/articles/PMC8391363/ /pubmed/34440256 http://dx.doi.org/10.3390/biomedicines9081052 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fujishiro, Midori
Ishihara, Hisamitsu
Ogawa, Katsuhiko
Murase, Takayo
Nakamura, Takashi
Watanabe, Kentaro
Sakoda, Hideyuki
Ono, Hiraku
Yamamotoya, Takeshi
Nakatsu, Yusuke
Asano, Tomoichiro
Kushiyama, Akifumi
Impact of Plasma Xanthine Oxidoreductase Activity on the Mechanisms of Distal Symmetric Polyneuropathy Development in Patients with Type 2 Diabetes
title Impact of Plasma Xanthine Oxidoreductase Activity on the Mechanisms of Distal Symmetric Polyneuropathy Development in Patients with Type 2 Diabetes
title_full Impact of Plasma Xanthine Oxidoreductase Activity on the Mechanisms of Distal Symmetric Polyneuropathy Development in Patients with Type 2 Diabetes
title_fullStr Impact of Plasma Xanthine Oxidoreductase Activity on the Mechanisms of Distal Symmetric Polyneuropathy Development in Patients with Type 2 Diabetes
title_full_unstemmed Impact of Plasma Xanthine Oxidoreductase Activity on the Mechanisms of Distal Symmetric Polyneuropathy Development in Patients with Type 2 Diabetes
title_short Impact of Plasma Xanthine Oxidoreductase Activity on the Mechanisms of Distal Symmetric Polyneuropathy Development in Patients with Type 2 Diabetes
title_sort impact of plasma xanthine oxidoreductase activity on the mechanisms of distal symmetric polyneuropathy development in patients with type 2 diabetes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391363/
https://www.ncbi.nlm.nih.gov/pubmed/34440256
http://dx.doi.org/10.3390/biomedicines9081052
work_keys_str_mv AT fujishiromidori impactofplasmaxanthineoxidoreductaseactivityonthemechanismsofdistalsymmetricpolyneuropathydevelopmentinpatientswithtype2diabetes
AT ishiharahisamitsu impactofplasmaxanthineoxidoreductaseactivityonthemechanismsofdistalsymmetricpolyneuropathydevelopmentinpatientswithtype2diabetes
AT ogawakatsuhiko impactofplasmaxanthineoxidoreductaseactivityonthemechanismsofdistalsymmetricpolyneuropathydevelopmentinpatientswithtype2diabetes
AT murasetakayo impactofplasmaxanthineoxidoreductaseactivityonthemechanismsofdistalsymmetricpolyneuropathydevelopmentinpatientswithtype2diabetes
AT nakamuratakashi impactofplasmaxanthineoxidoreductaseactivityonthemechanismsofdistalsymmetricpolyneuropathydevelopmentinpatientswithtype2diabetes
AT watanabekentaro impactofplasmaxanthineoxidoreductaseactivityonthemechanismsofdistalsymmetricpolyneuropathydevelopmentinpatientswithtype2diabetes
AT sakodahideyuki impactofplasmaxanthineoxidoreductaseactivityonthemechanismsofdistalsymmetricpolyneuropathydevelopmentinpatientswithtype2diabetes
AT onohiraku impactofplasmaxanthineoxidoreductaseactivityonthemechanismsofdistalsymmetricpolyneuropathydevelopmentinpatientswithtype2diabetes
AT yamamotoyatakeshi impactofplasmaxanthineoxidoreductaseactivityonthemechanismsofdistalsymmetricpolyneuropathydevelopmentinpatientswithtype2diabetes
AT nakatsuyusuke impactofplasmaxanthineoxidoreductaseactivityonthemechanismsofdistalsymmetricpolyneuropathydevelopmentinpatientswithtype2diabetes
AT asanotomoichiro impactofplasmaxanthineoxidoreductaseactivityonthemechanismsofdistalsymmetricpolyneuropathydevelopmentinpatientswithtype2diabetes
AT kushiyamaakifumi impactofplasmaxanthineoxidoreductaseactivityonthemechanismsofdistalsymmetricpolyneuropathydevelopmentinpatientswithtype2diabetes